var data={"title":"Atorvastatin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Atorvastatin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5681?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=atorvastatin-drug-information\" class=\"drug drug_general\">see &quot;Atorvastatin: Drug information&quot;</a> and <a href=\"topic.htm?path=atorvastatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Atorvastatin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137661\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lipitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50644078\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lipitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056610\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antilipemic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">HMG-CoA Reductase Inhibitor</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056603\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=atorvastatin-drug-information\" class=\"drug drug_general\">see &quot;Atorvastatin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Dosage should be individualized according to the baseline LDL-C level, the recommended goal of therapy, and patient response; adjustments should be made at intervals of 4 weeks (adults: 2 to 4 weeks).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Heterozygous familial and nonfamilial hypercholesterolemia:</b> Oral: <b>Note:</b> Begin treatment if after adequate trial of diet, the following are present: LDL-C &ge;190 mg/dL or LDL-C remains &ge;160 mg/dL and positive family history of premature cardiovascular disease or meets NCEP classification (NHLBI 2011). Therapy may be considered for children 8-9 years of age meeting the above criteria or for children with diabetes mellitus and LDL-C &ge;130 mg/dL (Daniels 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 6 to 10 years of age (Tanner stage I): Limited data available: Initial: 5 mg once daily; if LDL-C target not achieved after 4 weeks may increase to maximum daily dose: 10 mg/<b>day</b>; dosing based on trial which included 13 patients as part of a larger study population (n=45); efficacy and tolerability were similar to a group of children age 10 to 17 years receiving 10 to 20 mg/day (Gandelman 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents 10 to 17 years: Initial: 10 mg once daily; if LDL-C target not achieved after 4 weeks may increase to a maximum daily dose: 20 mg/<b>day</b>; doses &gt;20 mg have not been studied</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hyperlipidemia:</b> Oral: Children and Adolescents 10 to 17 years (males and postmenarchal females): Initial: 10 mg once daily; if LDL-C target not achieved after 1 to 3 months, may increase to a maximum daily dose: 20 mg/<b>day</b>; doses &gt;20 mg have not been studied (McCrindle 2007; NHLBI 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of graft coronary artery disease:</b> Limited data available: Oral: Children and Adolescents: 0.2 mg/kg/day rounded to nearest 2.5 mg increment; not to exceed age-appropriate doses (Chin 2002; Chin 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hypercholesterolemia (heterozygous familial and nonfamilial) and mixed hyperlipidemia (Fredrickson types IIa and IIb):</b> Oral: Initial: 10-20 mg once daily; patients requiring &gt;45% reduction in LDL-C may be started at 40 mg once daily; range: 10-80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Homozygous familial hypercholesterolemia:</b> Oral: 10-80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosage adjustment for atorvastatin with concomitant medications:</b> There are no recommendations in the manufacturer's labeling for patients &lt;18 years. In adolescents &ge;18 years, the following have been suggested:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Boceprevir, nelfinavir:</i> Use lowest effective atorvastatin dose; maximum daily dose: 40 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Clarithromycin, itraconazole, fosamprenavir, ritonavir (plus darunavir, fosamprenavir, or saquinavir):</i> Use lowest effective atorvastatin dose; maximum daily dose: 20 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Children &ge;10 years, Adolescents, and Adults: Because atorvastatin does not undergo significant renal excretion, dose modification is not necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer labeling; contraindicated in active liver disease or in patients with unexplained persistent elevations of serum transaminases.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137639\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lipitor: 10 mg, 20 mg, 40 mg, 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 40 mg, 80 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137625\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056614\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: May be taken without regard to meals or time of day. Swallow whole; do not break, crush, or chew.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F8002332\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056613\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Hyperlipidemia: Adjunct to dietary therapy in pediatric patients with heterozygous familial hypercholesterolemia if LDL-C remains &ge;190 mg/dL, if &ge;160 mg/dL with family history of premature CHD or presence of &ge;2 cardiovascular risk factors (FDA approved in boys and postmenarchal girls 10-17 years). Adjunct to dietary therapy to decrease elevated serum total and low density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo-B), and triglyceride levels, and to increase high density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia (heterozygous, familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb) (FDA approved in adults); treatment of homozygous familial hypercholesterolemia (FDA approved in adults); treatment of isolated hypertriglyceridemia (Fredrickson type IV); treatment of primary dysbetalipoproteinemia (Fredrickson Type III) (FDA approved in adults)</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Primary prevention of cardiovascular disease in high risk patients (FDA approved in adults); risk factors include: Age &ge;55 years, smoking, hypertension, low HDL-C, or family history of early coronary heart disease; secondary prevention of cardiovascular disease to reduce the risk of MI, stroke, revascularization procedures, and angina in patients with evidence of coronary heart disease and to reduce the risk of hospitalization for heart failure. Has also been used in prevention of graft coronary artery disease in heart transplant patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137707\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AtorvaSTATin may be confused with atoMOXetine, lovastatin, nystatin, pitavastatin, pravastatin, rosuvastatin, simvastatin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lipitor may be confused with labetalol, Levatol, lisinopril, Loniten, Lopid, Mevacor, Zocor, ZyrTEC </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137705\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hemorrhagic stroke</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Insomnia, malaise, myasthenia, nightmares</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Diabetes mellitus, hyperglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, cholestasis, diarrhea, dyspepsia, eructation, flatulence, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Urine abnormality (white blood cells positive in urine), urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Abnormal hepatic function tests, hepatitis, increased serum alkaline phosphatase, increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, increased creatine phosphokinase, joint swelling, limb pain, muscle fatigue, muscle spasm, myalgia, musculoskeletal pain, neck pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis, nasopharyngitis, pharyngolaryngeal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, alopecia, amnesia (reversible), anaphylaxis, anemia, angioedema, anorexia, back pain, bullous rash, chest pain, cognitive dysfunction (reversible), confusion (reversible), cystitis (interstitial; Huang 2015), depression, dizziness, dysgeusia, elevated glycosylated hemoglobin (HbA<sub>1c</sub>), erythema multiforme, fatigue, gynecomastia, hepatic failure, hypoesthesia, increased serum glucose, interstitial pulmonary disease, jaundice, memory impairment (reversible), myopathy, myositis, pancreatitis, paresthesia, peripheral edema, peripheral neuropathy, pruritus, rhabdomyolysis, rupture of tendon, Stevens-Johnson syndrome, thrombocytopenia, toxic epidermal necrolysis, vomiting, weight gain</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137646\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to atorvastatin or any component of the formulation; active liver disease; unexplained persistent elevations of serum transaminases; pregnancy or women who may become pregnant; breast-feeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137629\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Increases in HbA<sub>1c</sub> and fasting blood glucose have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: Persistent elevations in serum transaminases have been reported; upon dose reduction, drug interruption, or discontinuation, transaminase levels returned to or near pretreatment levels. Postmarketing reports of fatal and nonfatal hepatic failure have been reported and are rare. If serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatment, interrupt therapy promptly. If an alternate etiology is not identified, do not restart atorvastatin. Liver enzyme tests should be obtained at baseline and as clinically indicated and if signs/symptoms of liver injury occur. Ethanol may enhance the potential of adverse hepatic effects; instruct patients to avoid excessive ethanol consumption.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myopathy/rhabdomyolysis: Rhabdomyolysis with acute renal failure secondary to myoglobinuria and/or myopathy has been reported; patients should be monitored closely. This risk is dose-related and is increased with concurrent use of strong CYP3A4 inhibitors (eg, clarithromycin, itraconazole, protease inhibitors), cyclosporine, fibric acid derivatives (eg, gemfibrozil), or niacin (doses &ge;1 g/day); if concurrent use is warranted, consider lower starting and maintenance doses of atorvastatin. Use caution in patients with inadequately treated hypothyroidism, and those taking other drugs associated with myopathy (eg, colchicine); these patients are predisposed to myopathy. Uncomplicated myalgia immune-mediated necrotizing myopathy (IMNM) associated with HMG-CoA reductase inhibitors use has also been reported. Patients should be instructed to report unexplained muscle pain, tenderness, weakness, or brown urine, particularly if accompanied by malaise or fever. Discontinue therapy if markedly elevated CPK levels occur or myopathy is diagnosed/suspected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment and/or ethanol use: Use with caution in patients who consume large amounts of ethanol or have a history of liver disease; use is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; these patients are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stroke: Patients with recent stroke or TIA receiving long-term therapy with high-dose (ie, 80 mg/day) atorvastatin may be at increased risk for hemorrhagic stroke (SPARCL Investigators 2006). A subsequent post-hoc analysis demonstrated that patients with lacunar or hemorrhagic stroke may be at higher risk of hemorrhagic stroke; however, this finding was determined to be hypothesis generating. The overall benefit of treatment with atorvastatin (ie, reduced risk of stroke and cardiovascular events) in this population seems to outweigh the increased risk of hemorrhagic stroke if one truly exists (Goldstein 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in patients with advanced age, these patients are predisposed to myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: The manufacturer recommends temporary discontinuation for elective major surgery, acute medical or surgical conditions, or in any patient experiencing an acute, serious condition suggestive of a myopathy or having a risk factor predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis, hypotension, trauma, uncontrolled seizures, severe metabolic, endocrine, or electrolyte disorders). Based on current research and clinical guidelines, HMG-CoA reductase inhibitors should be continued in the perioperative period for noncardiac and cardiac surgery (ACC/AHA [Fleisher 2014]; ACC/AHA [Hillis 2011]). Perioperative discontinuation of statin therapy is associated with an increased risk of cardiac morbidity and mortality.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Secondary causes of hyperlipidemia should be ruled out prior to therapy. Atorvastatin has not been studied when the primary lipid abnormality is chylomicron elevation (Fredrickson types I and V).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137693\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (major), OATP1B1/SLCO1B1, P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP3A4 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137634\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12908&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: AtorvaSTATin may increase the serum concentration of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May increase the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: May increase the serum concentration of AtorvaSTATin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azithromycin (Systemic): May enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bexarotene (Systemic): May decrease the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bezafibrate: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: May increase the serum concentration of AtorvaSTATin. Management: Limit the atorvastatin maximum adult dose to 40 mg daily in patients receiving boceprevir.  Monitor clinical response to ensure that the lowest necessary atorvastatin dose is used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: AtorvaSTATin may enhance the adverse/toxic effect of Cimetidine. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofibrate: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid the use of HMG-CoA reductase inhibitors and ciprofibrate if possible. If concomitant therapy is considered, benefits should be carefully weighed against the risks, and patients should be monitored closely for signs/symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum dose of 20 mg/day (for adults) when used with clarithromycin.  If this combination is used, monitor patients more closely for evidence of atorvastatin toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of AtorvaSTATin. Management: Initiate atorvastatin at the lowest recommended dose and titrate slowly as needed while monitoring closely for evidence of atorvastatin toxicity. Atorvastatin dose should not exceed 20 mg/day with concurrent use of darunavir and cobicistat.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Colchicine may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of AtorvaSTATin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyproterone: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid use of statins metabolized by CYP3A4 (eg, simvastatin) and consider avoiding fluvastatin as well in patients receiving high dose cyproterone (300 mg/day). Consider use of pravastatin, rosuvastatin, or pitavastatin if statin therapy is needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: AtorvaSTATin may decrease the serum concentration of Dabigatran Etexilate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Danazol: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Concurrent use of simvastatin with danazol is contraindicated. Do not exceed 20 mg per day of lovastatin if combined with danazol. Fluvastatin, pravastatin, and rosuvastatin may pose lower risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DAPTOmycin: HMG-CoA Reductase Inhibitors (Statins) may enhance the adverse/toxic effect of DAPTOmycin. Specifically, the risk of skeletal muscle toxicity may be increased.  Management: Consider temporarily stopping HMG-CoA reductase inhibitor therapy prior to daptomycin.  If used together, regular (i.e., at least weekly) monitoring of CPK concentrations is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: AtorvaSTATin may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: AtorvaSTATin may increase the serum concentration of DilTIAZem. DilTIAZem may increase the serum concentration of AtorvaSTATin.  Management: Consider using lower atorvastatin doses when used together with diltiazem.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dofetilide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Dofetilide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May increase the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: May decrease the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: May increase the serum concentration of AtorvaSTATin. Management: Limit the dose of atorvastatin to a maximum of 20 mg/day when used together with elbasvir and grazoprevir.  Monitor closely for evidence of statin-related toxicities such as myalgia or myopathy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erythromycin (Systemic): May increase the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). This applies to atorvastatin, lovastatin and simvastatin. Conversely, levels of fluvastatin may be increased. Management: Dose adjustment of the HMG-CoA reductase inhibitor may be warranted. No interaction is expected with rosuvastatin, pravastatin, or pitavastatin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fenofibrate and Derivatives: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: May increase the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for muscle toxicities, including rhabdomyolysis may be significantly increased. Management: Avoid concurrent use whenever possible. Use is listed as contraindicated in product characteristic summaries in several countries, although UK labeling suggests that use could be considered under exceptional circumstances and with close supervision.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May enhance the myopathic (rhabdomyolysis) effect of AtorvaSTATin. Gemfibrozil may increase the serum concentration of AtorvaSTATin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: May increase the serum concentration of AtorvaSTATin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grapefruit Juice: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Avoid concurrent use of GFJ with lovastatin or simvastatin. Avoid high quantities of GFJ with atorvastatin.  Consider using a lower statin dose or a statin that is less likely to interact when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: May increase the serum concentration of AtorvaSTATin. Management: Limit the dose of atorvastatin to a maximum of 20 mg/day when used together with elbasvir and grazoprevir.  Monitor closely for evidence of statin-related toxicities such as myalgia or myopathy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of AtorvaSTATin. Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ketoconazole (Systemic): AtorvaSTATin may enhance the adverse/toxic effect of Ketoconazole (Systemic). Specifically, there is a theoretical potential for additive effects on reducing endogenous steroid concentrations. Ketoconazole (Systemic) may increase the serum concentration of AtorvaSTATin.  Management: Administer ketoconazole with atorvastatin cautiously, and monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities). Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lanthanum: HMG-CoA Reductase Inhibitors (Statins) may decrease the serum concentration of Lanthanum.  Management: Administer HMG-CoA reductase inhibitors at least two hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: May increase the serum concentration of AtorvaSTATin. Management: Limit the atorvastatin dose to 20 mg daily when combined with letermovir. When letermovir is coadministered with cyclosporine, the use of atorvastatin (at any dose) is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Patients on lomitapide 5 mg/day may continue that dose. Patients taking lomitapide 10 mg/day or more should decrease the lomitapide dose by half. The lomitapide dose may then be titrated up to a max adult dose of 30 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midazolam: AtorvaSTATin may increase the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacin: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Niacinamide: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inhibitors (Weak) may increase the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: AtorvaSTATin may enhance the hepatotoxic effect of PAZOPanib. AtorvaSTATin may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May increase the serum concentration of AtorvaSTATin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of AtorvaSTATin. Management: See full monograph for recommended dose limits. Avoid atorvastatin with tipranavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Consider using a lower starting dose and lower maintenance/maximum doses of atorvastatin, simvastatin, or lovastatin when used together with quinine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Red Yeast Rice: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: HMG-CoA Reductase Inhibitors (Statins) may increase the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rupatadine: May enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). Specifically, the risk for increased CPK and/or other muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of AtorvaSTATin. Management: The maximum atorvastatin dose should not exceed 40 mg/day with concurrent use of simeprevir, and use of the lowest necessary atorvastatin dose is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone: AtorvaSTATin may enhance the adverse/toxic effect of Spironolactone. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May increase the metabolism of HMG-CoA Reductase Inhibitors (Statins). Management: Consider avoiding the concomitant administration of St Johns Wort with interacting HMG-CoA reductase inhibitors in order to avoid the potential for decreased antilipemic effects. Monitor for decreased effects during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: May increase the serum concentration of AtorvaSTATin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telithromycin: May increase the serum concentration of AtorvaSTATin. Management: Consider limiting atorvastatin to a max (adult) dose of 20 mg/day when used with telithromycin.  Although not a specific recommendation in atorvastatin labeling, this is consistent with dosing for other strong CYP3A4 inhibitors, including clarithromycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: May increase the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: May increase the serum concentration of AtorvaSTATin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: HMG-CoA Reductase Inhibitors (Statins) may enhance the myopathic (rhabdomyolysis) effect of Trabectedin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: May increase the serum concentration of AtorvaSTATin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Verapamil: AtorvaSTATin may increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin.  Management: Consider using lower atorvastatin doses when used together with verapamil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of AtorvaSTATin. Management: Monitor for toxic effects of atorvastatin (e.g., myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment, and reduce atorvastatin dose when possible. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: May increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). Management: Use the lowest statin dose possible if combined with voxilaprevir and monitor patients for increased statin effects/toxicities. Avoid concomitant use of voxilaprevir with rosuvastatin or pitavastatin, and limit pravastatin doses to 40 mg daily.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137658\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Atorvastatin serum concentrations may be increased by grapefruit juice. Management: Avoid concurrent intake of large quantities of grapefruit juice (&gt;1 quart/day). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137635\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1757842\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Studies in animals and pregnant women have shown evidence of fetal abnormalities and use is contraindicated in women who are or may become pregnant. There are reports of congenital anomalies following maternal use of HMG-CoA reductase inhibitors in pregnancy; however, maternal disease, differences in specific agents used, and the low rates of exposure limit the interpretation of the available data (Godfrey 2012; Lecarpentier 2012). Cholesterol biosynthesis may be important in fetal development; serum cholesterol and triglycerides increase normally during pregnancy. The discontinuation of lipid lowering medications temporarily during pregnancy is not expected to have significant impact on the long term outcomes of primary hypercholesterolemia treatment.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Because they are potentially teratogenic, the ADA Diabetes guidelines recommends avoiding use of HMG-CoA reductase inhibitors in sexually active women of childbearing age who are not using reliable contraception (ADA 2018b). If treatment of dyslipidemias is needed in pregnant women or in women of reproductive age, other agents are preferred (Berglund 2012; Stone 2013). The manufacturer recommends administration to women of childbearing potential only when conception is highly unlikely and patients have been informed of potential hazards.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1056609\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric patients: Baseline: ALT, AST, and creatine phosphokinase levels (CPK); fasting lipid panel (FLP) and repeat ALT and AST should be checked after 4 weeks of therapy; if no myopathy symptoms or laboratory abnormalities, then monitor FLP, ALT , and AST every 3 to 4 months during the first year and then every 6 months thereafter (NHLBI, 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults: </p>\n    <p style=\"text-indent:-4em;margin-left:6em;\">\n      <i>2013 ACC/AHA Blood Cholesterol Guideline recommendations</i> (Stone, 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Lipid panel (total cholesterol, HDL, LDL, triglycerides):</b> Baseline lipid panel; fasting lipid profile within 4 to 12 weeks after initiation or dose adjustment and every 3 to 12 months (as clinically indicated) thereafter. If 2 consecutive LDL levels are &lt;40 mg/dL, consider decreasing the dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Hepatic transaminase levels:</b> Baseline measurement of hepatic transaminase levels (ie, ALT); measure hepatic function if symptoms suggest hepatotoxicity (eg, unusual fatigue or weakness, loss of appetite, abdominal pain, dark-colored urine or yellowing of skin or sclera) during therapy. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>CPK:</b> CPK should not be routinely measured. Baseline CPK measurement is reasonable for some individuals (eg, family history of statin intolerance or muscle disease, clinical presentation, concomitant drug therapy that may increase risk of myopathy). May measure CPK in any patient with symptoms suggestive of myopathy (pain, tenderness, stiffness, cramping, weakness, or generalized fatigue).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Evaluate for new-onset diabetes mellitus during therapy; if diabetes develops, continue statin therapy and encourage adherence to a heart-healthy diet, physical activity, a healthy body weight, and tobacco cessation. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">If patient develops a confusional state or memory impairment, may evaluate patient for nonstatin causes (eg, exposure to other drugs), systemic and neuropsychiatric causes, and the possibility of adverse effects associated with statin therapy.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">\n      <i>Manufacturer recommendation:</i> Liver enzyme tests at baseline and repeated when clinically indicated. Measure CPK when myopathy is being considered or may measure CPK periodically in high risk patients (eg, drug-drug interaction). Upon initiation or titration, lipid panel should be analyzed within 2 to 4 weeks. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137628\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in cholesterol synthesis (reduces the production of mevalonic acid from HMG-CoA); this then results in a compensatory increase in the expression of LDL receptors on hepatocyte membranes and a stimulation of LDL catabolism. In addition to the ability of HMG-CoA reductase inhibitors to decrease levels of high-sensitivity C-reactive protein (hsCRP), they also possess pleiotropic properties including improved endothelial function, reduced inflammation at the site of the coronary plaque, inhibition of platelet aggregation, and anticoagulant effects (de Denus 2002; Ray 2005).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137645\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Initial changes: 3 to 5 days; Maximal reduction in plasma cholesterol and triglycerides: 2 to 4 weeks; LDL reduction: 10 mg/day: 39% (for each doubling of this dose, LDL is lowered approximately 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapidly absorbed; extensive first-pass metabolism in GI mucosa and liver </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~381 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &ge;98% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via CYP3A4; forms active ortho- and parahydroxylated derivatives and an inactive beta-oxidation product; plasma concentrations are elevated in patients with chronic alcoholic liver disease and Childs-Pugh class A and B liver disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~14% (parent drug); ~30% (parent drug and equipotent metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Parent drug: ~14 hours; Equipotent metabolites: 20 to 30 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Bile (following hepatic and/or extra-hepatic metabolism; does not appear to undergo enterohepatic recirculation); urine (&lt;2% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137648\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Atorvastatin Calcium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $355.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $494.89</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $506.98</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (90): $510.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Lipitor Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $1,077.92</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $1,537.62</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,793.93</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (90): $1,537.62</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F137650\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acrovastin (EC);</li>\n      <li>Actalipid (ID);</li>\n      <li>Aditor (JO, LB);</li>\n      <li>Aforsatin (VN);</li>\n      <li>Ale (CN);</li>\n      <li>Alipid (VN);</li>\n      <li>Amicor (RO);</li>\n      <li>Analip (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Anxolipo (TW);</li>\n      <li>Aspavor (ZW);</li>\n      <li>Astatin (QA);</li>\n      <li>Astator (SI);</li>\n      <li>Atacor (HK, MT);</li>\n      <li>Atarva (AR);</li>\n      <li>Atasin (BD);</li>\n      <li>Ateroz (ET);</li>\n      <li>Atofar (ID);</li>\n      <li>Atokor (UA);</li>\n      <li>Atolow (KR);</li>\n      <li>Atopitar (PH);</li>\n      <li>Ator (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, PH, SA, SY, YE);</li>\n      <li>Atorcad (PH);</li>\n      <li>Atorcal (TW);</li>\n      <li>Atorin (AU, TW);</li>\n      <li>Atoris (BE, ES, HU, LT, LV, RU, SG);</li>\n      <li>Atorlip (CO, HK, LB, PE, VN);</li>\n      <li>Atorlog (VN);</li>\n      <li>Atorphil (PH);</li>\n      <li>Atorsan (ID);</li>\n      <li>Atorva (KR, LK, SA);</li>\n      <li>Atorvachol (AU);</li>\n      <li>Atorvaright (HK);</li>\n      <li>Atorvas (IE, MY);</li>\n      <li>Atorwin (ID, PH);</li>\n      <li>Atoty (TW);</li>\n      <li>Atroact-10 (PH);</li>\n      <li>Atrofit (TZ);</li>\n      <li>Atstat (LK);</li>\n      <li>Atswift (SG);</li>\n      <li>Atvas (LK);</li>\n      <li>Avamax (PH);</li>\n      <li>Axo (DO, GT, HN, NI, PA, SV);</li>\n      <li>Bestatin (PH);</li>\n      <li>Carditor (TZ);</li>\n      <li>Cardyl (ES);</li>\n      <li>Carvastin (PH);</li>\n      <li>Cheklip (VN);</li>\n      <li>Chlovas (TH);</li>\n      <li>Citalor (BR);</li>\n      <li>Colestop (ET);</li>\n      <li>Covetor (ID);</li>\n      <li>Debostin (ID);</li>\n      <li>Divator (HK);</li>\n      <li>Enturion (SG);</li>\n      <li>Fastor (ID);</li>\n      <li>Hipolixan (CL);</li>\n      <li>Leztrol (PH);</li>\n      <li>Lipicon (LK);</li>\n      <li>Lipiduce (HK, MY);</li>\n      <li>Lipigo (PH);</li>\n      <li>Lipikhan (HK, PH);</li>\n      <li>Lipilou (KR);</li>\n      <li>Lipinon (KR);</li>\n      <li>Lipistad (HK, MY);</li>\n      <li>Lipitas (ET, ZW);</li>\n      <li>Lipiterol (KR);</li>\n      <li>Lipitin (HR);</li>\n      <li>Lipitor (AE, AR, AU, BB, BD, BE, BF, BH, BJ, BO, BR, CI, CL, CN, CO, CR, CY, DO, EC, EE, EG, ET, FI, GB, GH, GM, GN, GR, GT, HK, HN, ID, IE, IL, IQ, IR, JO, JP, KE, KR, KW, LB, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PR, PY, QA, SA, SC, SD, SE, SG, SL, SN, SV, SY, TH, TN, TR, TW, TZ, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Lipivent (PH);</li>\n      <li>Lipiwon (KR);</li>\n      <li>Lipoactin (KR);</li>\n      <li>Lipodar (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Lipodemin (UA);</li>\n      <li>Lipofix (ZW);</li>\n      <li>Lipomax (PY, QA, SA);</li>\n      <li>Lipomet (KR);</li>\n      <li>Liponorm (EC);</li>\n      <li>Lipox (CL);</li>\n      <li>Litorva (IL, UA);</li>\n      <li>Lopamol (LT);</li>\n      <li>Lorstat (AU);</li>\n      <li>Lowlipen (CO);</li>\n      <li>Neustatin-A (KR);</li>\n      <li>Newvast (KR);</li>\n      <li>Olpit (KR);</li>\n      <li>Orvakline (MY);</li>\n      <li>Pelearto (VN);</li>\n      <li>Plan (AR);</li>\n      <li>Rotaqor (MY);</li>\n      <li>Saatin (PH);</li>\n      <li>Shanleting (CN);</li>\n      <li>Simtor (ID);</li>\n      <li>Sortis (AT, BG, CH, CZ, DE, HR, LV, PL, SE, SI, SK);</li>\n      <li>Statol (TR);</li>\n      <li>Stator (ID);</li>\n      <li>Stavinor (ID);</li>\n      <li>Storvas (IN, MY, ZW);</li>\n      <li>Tahor (FR, MU);</li>\n      <li>TG-Tor (ZW);</li>\n      <li>Tolevas (UA);</li>\n      <li>Torid (IL);</li>\n      <li>Torolac (JO);</li>\n      <li>Torvacol (IE, QA);</li>\n      <li>Torvalipin (SG);</li>\n      <li>Torvast (IT);</li>\n      <li>Torvatec (SG);</li>\n      <li>Torvazin (VN);</li>\n      <li>Tovast (KR);</li>\n      <li>Trovas (AU);</li>\n      <li>Truvast (PH);</li>\n      <li>Truvaz (ID);</li>\n      <li>Tulip (SG, SK, TW);</li>\n      <li>Vastor (JO);</li>\n      <li>Vaztor (PH);</li>\n      <li>X-Tor (LK);</li>\n      <li>Xantor (PH);</li>\n      <li>Xarator (TH);</li>\n      <li>Xelpid (LK);</li>\n      <li>Xentor (PH);</li>\n      <li>Xerova (BD);</li>\n      <li>You Jia (CN);</li>\n      <li>Zapitor (BD);</li>\n      <li>Zarator (AR, CL, DK, ES, NZ, PT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Diabetes Association, &quot;Standards of Medical Care in Diabetes-2013,&quot;<i> Diabetes Care</i>, 2013, 36(Suppl 1):S11-66.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Belay B, Belamarich PF, and Tom-Revzon C, &quot;The Use of Statins in Pediatrics: Knowledge Base, Limitations, and Future Directions,&quot; <i>Pediatrics</i>, 2007, 119(2):370-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/17272627/pubmed\" target=\"_blank\" id=\"17272627\">17272627</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Berglund L, Brunzell JD, Goldberg AC, et al, &ldquo;Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2012, 97(9):2969-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/22962670/pubmed\" target=\"_blank\" id=\"22962670\">22962670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chin C, Gamberg P, Miller J, et al, &quot;Efficacy and Safety of Atorvastatin After Pediatric Heart Transplantation,&quot; <i>J Heart Lung Transplant</i>, 2002, 21(11):1213-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/12431495/pubmed\" target=\"_blank\" id=\"12431495\">12431495</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chin C, Lukito SS, Shek J, et al, &quot;Prevention of Pediatric Graft Coronary Artery Disease: Atorvastatin,&quot; <i>Pediatr Transplant</i>, 2008, 12(4):442-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18466431/pubmed\" target=\"_blank\" id=\"18466431\">18466431</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daniels SR, Greer FR, and Committee on Nutrition, &quot;Lipid Screening and Cardiovascular Health in Childhood,&quot; <i>Pediatrics</i>, 2008, 122(1):198-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18596007/pubmed\" target=\"_blank\" id=\"18596007\">18596007</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Denus S and Spinler SA, &ldquo;Early Statin Therapy for Acute Coronary Syndromes,&rdquo; <i>Ann Pharmacother</i>, 2002, 36(11):1749-58. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/12398573/pubmed\" target=\"_blank\" id=\"12398573\">12398573</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; <i>JAMA</i>, 2001, 285(19):2486-97. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/11368702/pubmed\" target=\"_blank\" id=\"11368702\">11368702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Godfrey LM, Erramouspe J, and Cleveland KW, &quot;Teratogenic Risk of Statins in Pregnancy,&quot; <i>Ann Pharmacother</i>, 2012, 46(10):1419-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/23032657/pubmed\" target=\"_blank\" id=\"23032657\">23032657</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldstein LB, Amarenco P, Szarck M, et al, &ldquo;Hemorrhagic Stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Study,&rdquo; <i>Neurology</i>, 2008, 70(24 Pt 2):2364-70.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/18077795/pubmed\" target=\"_blank\" id=\"18077795\">18077795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lecarpentier E, Morel O, Fournier T, et al, &quot;Statins and Pregnancy: Between Supposed Risks and Theoretical Benefits,&quot; <i>Drugs</i>, 2012, 72(6):773-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/22480340/pubmed\" target=\"_blank\" id=\"22480340\">22480340</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Ose L, and Marais AD, &ldquo;Efficacy and Safety of Atorvastatin in Children and Adolescents With Familial Hypercholesterolemia or Severe Hyperlipidemia: A Multicenter, Randomized, Placebo-Controlled Trial,&rdquo; <i>J Pediatr</i>, 2003, 143(1):74-80. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/12915827/pubmed\" target=\"_blank\" id=\"12915827\">12915827</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McCrindle BW, Urbina EM, Dennison BA, et al, &quot;Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement From the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing,&quot; <i>Circulation</i>, 2007, 115(14):1948-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/17377073/pubmed\" target=\"_blank\" id=\"17377073\">17377073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute, &quot;Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,&quot; Clinical Practice Guidelines, 2011, National Institutes of Health. Available at  <a href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf%20\" target=\"_blank\">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ray KK and Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. <i>J Am Coll Cardiol</i>. 2005;46(8):1425-1433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atorvastatin-pediatric-drug-information/abstract-text/16226165/pubmed\" target=\"_blank\" id=\"16226165\">16226165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stone NJ, Robinson J, Lichtenstein AH, et al, 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013].<i>Circulation</i>. 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; May 2001, www.nhlbi.nih.gov/guidelines/cholesterol.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12908 Version 256.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F137661\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50644078\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1056610\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1056603\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F137639\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F137625\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1056614\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F8002332\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1056613\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F137707\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F137705\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F137646\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F137629\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F137693\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F137634\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F137658\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F137635\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1757842\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1056609\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F137628\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F137645\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F137648\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F137650\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12908|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=atorvastatin-drug-information\" class=\"drug drug_general\">Atorvastatin: Drug information</a></li><li><a href=\"topic.htm?path=atorvastatin-patient-drug-information\" class=\"drug drug_patient\">Atorvastatin: Patient drug information</a></li></ul></div></div>","javascript":null}